CAS NO: | 2503-26-6 |
包装: | 1mg |
市场价: | 8778元 |
Physical Appearance | A powder |
Storage | Store at -20°C |
M.Wt | 593.8 |
Cas No. | 2503-26-6 |
Formula | C30H51N5O7 |
Synonyms | SB 242536,NSC 236580 |
Solubility | ≤10mg/ml in dichloromethane,;10mg/ml in methanol;10mg/ml in ethyl acetate |
Chemical Name | cyclo[N-methyl-L-alanyl-β-alanyl-(2R)-2-hydroxy-4-methylpentanoyl-L-prolyl-L-isoleucyl-N-methyl-L-valyl] |
Canonical SMILES | O=C(N[C@]([C@@H](C)CC)([H])C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1C)=O)=O)[C@@]2([H])N(CCC2)C([C@@H](CC(C)C)OC(CCNC1=O)=O)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Destruxin B, a cyclic hexadepsipeptide mycotoxin, has been reported to have insecticidal and phytotoxic activity and can also induce apoptosis.
Mycotoxins has been identified as a class of toxic secondary metabolites produced by organisms of the fungus kingdom and are able to cause disease and death in both humans and animals.
In vitro: The results of a previous study showed that destruxin B exhibited selective and significant time- and dose-dependent inhibitory effects on the viabilities of GNM and TSCCa cells but not on GF cells. These findings indicated that destruxin B was able to induce tumor specific growth inhibition in cancer cells through Bax/Bcl-2-mediated intrinsic mitochondrial apoptotic pathway in both time- and dose-dependent manners [1].
In vivo: Animal study found that the daily subcutaneously administered destruxin B at 0.6-15 mg/kg was safe and effective in inhibiting the growth of CRC cells. In addition, the expression of cleaved poly (ADP-ribose) polymerase, Bax, as well as active caspase-3 were observed with destruxin B treatment. Moreover, the increase in tumor volumes of destruxin B treated groups were significantly lower than those of the mock-treated group [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Huang Liu R, Chen SP, Lu TM, Tsai WY, Tsai CH, Yang CC1, Tzeng YM. Selective apoptotic cell death effects of oral cancer cells treated with destruxin B. BMC Complement Altern Med. 2014 Jun 28;14:207. doi: 10.1186/1472-6882-14-207.
[2] Lee YP, Wang CW, Liao WC, Yang CR, Yeh CT, Tsai CH, Yang CC, Tzeng YM. In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. Anticancer Res. 2012 Jul;32(7):2735-45.